These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27029697)

  • 1. Biologicals in Juvenile Idiopathic Arthritis.
    Saini I; Dawman L; Gupta N; Kabra SK
    Indian Pediatr; 2016 Mar; 53(3):260-1. PubMed ID: 27029697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database.
    Cabrera N; Lega JC; Kassai B; Wouters C; Kondi A; Cannizzaro E; Woerner A; Chausset A; Roethlisberger S; Jeanneret C; Aeschlimann F; Malik S; Duquesne A; Kaiser D; Higel L; Maes A; Berthet G; Hentgen V; Kone-Paut I; Belot A; Hofer M
    Joint Bone Spine; 2019 May; 86(3):343-350. PubMed ID: 30201476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
    Davies R; Gaynor D; Hyrich KL; Pain CE
    Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials.
    Amarilyo G; Tarp S; Foeldvari I; Cohen N; Pope TD; Woo JM; Christensen R; Furst DE
    Semin Arthritis Rheum; 2016 Dec; 46(3):312-318. PubMed ID: 27989499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benefit-risk balance for biological agents in juvenile idiopathic arthritis: a meta-analysis of randomized clinical trials.
    Cabrera N; Avila-Pedretti G; Belot A; Larbre JP; Mainbourg S; Duquesne A; Janiaud P; Kassai B; Cucherat M; Lega JC
    Rheumatology (Oxford); 2020 Sep; 59(9):2226-2236. PubMed ID: 32449926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
    Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Sztajnbok F; Goldenstein-Schainberg C; Scheinberg M; Penades IC; Fischbach M; Orozco J; Hashkes PJ; Hom C; Jung L; Lepore L; Oliveira S; Wallace CA; Sigal LH; Block AJ; Covucci A; Martini A; Giannini EH; ;
    Lancet; 2008 Aug; 372(9636):383-91. PubMed ID: 18632147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biological therapy treatment of juvenile idiopathic arthritis].
    Herlin T
    Ugeskr Laeger; 2008 Jun; 170(24):2105-8. PubMed ID: 18565289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept.
    Verazza S; Davì S; Consolaro A; Bovis F; Insalaco A; Magni-Manzoni S; Nicolai R; Marafon DP; De Benedetti F; Gerloni V; Pontikaki I; Rovelli F; Cimaz R; Marino A; Zulian F; Martini G; Pastore S; Sandrin C; Corona F; Torcoletti M; Conti G; Fede C; Barone P; Cattalini M; Cortis E; Breda L; Olivieri AN; Civino A; Podda R; Rigante D; La Torre F; D'Angelo G; Jorini M; Gallizzi R; Maggio MC; Consolini R; De Fanti A; Muratore V; Alpigiani MG; Ruperto N; Martini A; Ravelli A;
    Pediatr Rheumatol Online J; 2016 Dec; 14(1):68. PubMed ID: 27993144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
    Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
    J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis.
    Birolo C; Zannin ME; Arsenyeva S; Cimaz R; Miserocchi E; Dubko M; Deslandre CJ; Falcini F; Alessio M; La Torre F; Denisova E; Martini G; Nikishina I; Zulian F
    J Rheumatol; 2016 Nov; 43(11):2068-2073. PubMed ID: 27633826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Juvenile idiopathic arthritis: therapies in the 21st century.
    Haines KA
    Bull NYU Hosp Jt Dis; 2007; 65(3):205-11. PubMed ID: 17922671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept treatment for children with refractory juvenile idiopathic arthritis.
    Kuo HC; Yu HR; Wu CC; Chang LS; Yang KD
    J Microbiol Immunol Infect; 2011 Feb; 44(1):52-6. PubMed ID: 21531353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of juvenile idiopathic arthritis in the biologic age.
    Stoll ML; Cron RQ
    Rheum Dis Clin North Am; 2013 Nov; 39(4):751-66. PubMed ID: 24182853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.
    Kahn R; Berthold E; Gullstrand B; Schmidt T; Kahn F; Geborek P; Saxne T; Bengtsson AA; Månsson B
    Acta Paediatr; 2016 Apr; 105(4):427-32. PubMed ID: 26707699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?
    Tappeiner C; Heinz C; Ganser G; Heiligenhaus A
    J Rheumatol; 2012 Jun; 39(6):1294-5. PubMed ID: 22661419
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.
    Lovell DJ; Ruperto N; Mouy R; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhaes C; Chavez-Corrales J; Huemer C; Kivitz A; Blanco FJ; Foeldvari I; Hofer M; Huppertz HI; Job Deslandre C; Minden K; Punaro M; Block AJ; Giannini EH; Martini A;
    Arthritis Rheumatol; 2015 Oct; 67(10):2759-70. PubMed ID: 26097215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trials reveal promising options for treating juvenile rheumatoid arthritis.
    Hampton T
    JAMA; 2008 Jan; 299(1):27-8. PubMed ID: 18167400
    [No Abstract]   [Full Text] [Related]  

  • 19. Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.
    Constantin T; Foeldvari I; Vojinovic J; Horneff G; Burgos-Vargas R; Nikishina I; Akikusa JD; Avcin T; Chaitow J; Koskova E; Lauwerys BR; Calvo Penades I; Flato B; Gamir ML; Huppertz HI; Jaller Raad JJ; Jarosova K; Anton J; Macku M; Otero Escalante WJ; Rutkowska-Sak L; Trauzeddel R; Velez-Sanchez PJ; Wouters C; Wajdula J; Zang C; Bukowski J; Woodworth D; Vlahos B; Martini A; Ruperto N;
    J Rheumatol; 2016 Apr; 43(4):816-24. PubMed ID: 26932344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis.
    Nicolai R; Cortis E; Ravà L; Bracaglia C; Pardeo M; Insalaco A; Buonuomo PS; Tozzi AE; De Benedetti F
    J Pediatric Infect Dis Soc; 2016 Mar; 5(1):76-9. PubMed ID: 26908493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.